SAN FRANCISCO, Dec. 13, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced the appointment of Mark A.
Goldberg, M.D. to its board of directors.
"We are delighted to welcome Mark to our board of directors,"
stated Matthew R. Patterson,
President and Chief Executive Officer of Audentes. "Mark is a
recognized industry leader with a background in the development of
novel therapies to treat severe rare diseases. His
demonstrated track-record in clinical development, regulatory
affairs and corporate strategy will be an important asset for
Audentes as we continue to advance our pipeline of innovative gene
therapy products."
Dr. Goldberg is a rare disease leader who brings over 20 years
of experience developing and commercializing products to address
serious unmet medical needs. Earlier in his career, Dr.
Goldberg served as the Executive Vice President, Global Medical and
Regulatory Strategy at Synageva, with responsibility for medical
and regulatory affairs. He previously served as Senior Vice
President for Clinical Development and Global Therapeutic Group
Head for Oncology and Personalized Genetic Health at Genzyme
Corporation, where he was responsible for leading clinical
development teams for all drugs in development in those therapeutic
areas. While at Genzyme he played a central role in the
development and approval of multiple innovative rare disease
therapeutics, including Fabrazyme®, Aldurazyme®, Myozyme® and
Lumizyme®. Dr. Goldberg is a board-certified medical
oncologist and hematologist, holds appointments at Brigham and
Women's Hospital and the Dana Farber Cancer Institute, and received
his A/B from Harvard College and his M.D.
from Harvard Medical School.
"I am very pleased to join the Audentes board of directors
during this transformational time for the company," commented Dr.
Goldberg. "Audentes has firmly established itself as a leader
in the emerging field of gene therapy and is well-positioned for
meaningful upcoming catalysts, including preliminary efficacy data
from its lead XLMTM program, the initiation of a Phase 1/2 study in
its Crigler-Najjar program and the advancement of its Pompe disease
and cardiac gene therapy programs. I look forward to working
closely with the Audentes board and management team during what
promises to be an exciting 2018."
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases.
We are currently conducting a Phase 1/2 clinical study of our lead
product candidate AT132 for the treatment of X-Linked Myotubular
Myopathy (XLMTM) and have three additional product candidates in
development, including AT342 for the treatment of Crigler-Najjar
Syndrome, AT982 for the treatment of Pompe disease, and AT307 for
the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic
Ventricular Tachycardia (CASQ2-CPVT). We are a focused,
experienced and passionate team committed to forging strong, global
relationships with the patient, research and medical
communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to: the timing of preliminary data from
ASPIRO, the Phase 1/2 study of AT132 to treat XLMTM, and the timing
of initiating the Phase 1/2 clinical study of AT342. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements. Although the
company believes that the expectations reflected in such
forward-looking statements are reasonable, the company cannot
guarantee future events, results, actions, levels of activity,
performance or achievements, and the timing and results of
biotechnology development and potential regulatory approval is
inherently uncertain. Forward-looking statements are subject
to risks and uncertainties that may cause the company's actual
activities or results to differ significantly from those expressed
in any forward-looking statement, including risks and uncertainties
related to the company's ability to advance its product candidates,
obtain regulatory approval of and ultimately commercial its product
candidates, the timing and results of preclinical and clinical
trials, the company's ability to fund development activities and
achieve development goals, the company's ability to protect
intellectual property and other risks and uncertainties
described under the heading "Risk Factors" in documents the company
files from time to time with the Securities and Exchange
Commission. These forward-looking statements speak only as of
the date of this press release, and the company undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Audentes Contacts:
Investor Contact:
Andrew Chang, Investor Relations
415.818.1033
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-appoints-mark-a-goldberg-md-to-its-board-of-directors-300570334.html
SOURCE Audentes Therapeutics, Inc.